The 12 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 81.50, with a high estimate of 104.00 and a low estimate of 52.00. The median estimate represents a +64.85% increase from the last price of 49.44.
The current consensus among 15 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.05
Reporting Date May 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.